CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37534980.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1333 and PMC identifier 10592266.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this CCR Translations, we discuss the potential for tumor-infiltrating lymphocyte therapy to overcome immune checkpoint inhibitor resistance through CD4+-mediated and MHC-II-dependent killing. Validating these results from human tumors has potential to improve the clinical application of adoptive cellular transfer in advanced cancers. See related article by Draghi et al., p. 3937.
Medical subject headings
- Lymphocytes, Tumor-Infiltrating
- Melanoma